Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-09 00:46:44 UTC - HELPFUL

Rated by Participant: 0F44EBEB519364679828F1F0E1AC49C4AF5CB2803CCFF5FE8020D9974DBEBC9B
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 0F44EBEB519364679828F1F0E1AC49C4AF5CB2803CCFF5FE8020D9974DBEBC9B
createdAtMillis - 1688863604476
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 1
helpfulEmpathetic - 0
helpfulGoodSources - 0
helpfulUniqueContext - 0
helpfulAddressesClaim - 0
helpfulImportantContext - 0
helpfulUnbiasedLanguage - 0
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 0
ratingsId - 16778032330775224320F44EBEB519364679828F1F0E1AC49C4AF5CB2803CCFF5FE8020D9974DBEBC9B